Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal

06:40 EST 14 Feb 2019 | Pharmafile

Novartis has arranged to sell the remainder of its rights to its skin and lung cancer drug Proleukin (aldesleukin, recombinant interleukin-2) to Clinigen in a deal worth $210 million, it has emerged.

The agreement breaks down into an initial payment by Clinigen of $120 million, with $60 million to follow deferred over the 12 months following the deal’s completion. The rest will be paid in milestone payments, subject to sales performance.

Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal

Novartis has arranged to sell the remainder of its rights to its skin and lung cancer drug Proleukin (aldesleukin, recombinant interleukin-2) to Clinigen in a deal worth $210 million, it has emerged.

More From BioPortfolio on "Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal"